LT3897697T - Peptidai, skirti diabeto ir susijusių sutrikimų gydymui ir profilaktikai - Google Patents
Peptidai, skirti diabeto ir susijusių sutrikimų gydymui ir profilaktikaiInfo
- Publication number
- LT3897697T LT3897697T LTEPPCT/EP2019/086573T LTEP2019086573T LT3897697T LT 3897697 T LT3897697 T LT 3897697T LT EP2019086573 T LTEP2019086573 T LT EP2019086573T LT 3897697 T LT3897697 T LT 3897697T
- Authority
- LT
- Lithuania
- Prior art keywords
- diabetes
- peptides
- prevention
- treatment
- associated disorders
- Prior art date
Links
- 206010012601 diabetes mellitus Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4866—Protein C (3.4.21.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6464—Protein C (3.4.21.69)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/11—Protein-serine/threonine kinases (2.7.11)
- C12Y207/11013—Protein kinase C (2.7.11.13)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21069—Protein C activated (3.4.21.69)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18306794 | 2018-12-21 | ||
| PCT/EP2019/086573 WO2020127904A1 (en) | 2018-12-21 | 2019-12-20 | Peptides for treatment and prevention of diabetes and associated disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT3897697T true LT3897697T (lt) | 2023-07-10 |
Family
ID=65200524
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEPPCT/EP2019/086573T LT3897697T (lt) | 2018-12-21 | 2019-12-20 | Peptidai, skirti diabeto ir susijusių sutrikimų gydymui ir profilaktikai |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20220133860A1 (lt) |
| EP (2) | EP3897697B1 (lt) |
| JP (2) | JP7335337B2 (lt) |
| KR (2) | KR102555817B1 (lt) |
| CN (2) | CN116196399A (lt) |
| AU (1) | AU2019408382A1 (lt) |
| BR (1) | BR112021012134A2 (lt) |
| CA (1) | CA3124260C (lt) |
| CY (1) | CY1126054T1 (lt) |
| DK (1) | DK3897697T3 (lt) |
| EA (1) | EA202191758A1 (lt) |
| ES (1) | ES2948264T3 (lt) |
| FI (1) | FI3897697T3 (lt) |
| HR (1) | HRP20230591T1 (lt) |
| HU (1) | HUE062537T2 (lt) |
| IL (1) | IL284029B2 (lt) |
| LT (1) | LT3897697T (lt) |
| MX (1) | MX2021007460A (lt) |
| PL (1) | PL3897697T3 (lt) |
| PT (1) | PT3897697T (lt) |
| RS (1) | RS64265B1 (lt) |
| SG (1) | SG11202107923WA (lt) |
| SI (1) | SI3897697T1 (lt) |
| WO (1) | WO2020127904A1 (lt) |
| ZA (1) | ZA202105101B (lt) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022098051A1 (ko) | 2020-11-05 | 2022-05-12 | 한국생명공학연구원 | 항염 및 조직 재생작용을 갖는 신규 펩타이드 |
| WO2023214802A1 (ko) | 2022-05-03 | 2023-11-09 | 한국생명공학연구원 | 신규 펩타이드 및 이의 항염 및 재생 용도 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002525382A (ja) * | 1998-09-25 | 2002-08-13 | ザ チルドレンズ メディカル センター コーポレイション | プロテインキナーゼの活性を選択的に調節するショートペプチド |
| TW200303742A (en) | 2001-11-21 | 2003-09-16 | Novartis Ag | Organic compounds |
| ATE442365T1 (de) | 2003-05-20 | 2009-09-15 | Novartis Pharma Gmbh | N-acyl stickstoffheterocyclen als liganden von peroxisom-proliferator-aktivierten rezeptoren |
| ES2309766T3 (es) | 2004-06-04 | 2008-12-16 | Camurus Ab | Formulaciones liquidas de liberacion lenta. |
| PL1843746T3 (pl) | 2005-01-14 | 2011-09-30 | Camurus Ab | Formulacje analogów somatostatyny |
| US8575307B2 (en) * | 2005-06-29 | 2013-11-05 | Hadasit Medical Research Services & Development Ltd. | Protein kinase C inhibitors for prevention of insulin resistance and type 2 diabetes |
| WO2010011313A2 (en) | 2008-07-23 | 2010-01-28 | President And Fellows Of Harvard College | Ligation of stapled polypeptides |
| US8586707B2 (en) | 2008-09-16 | 2013-11-19 | The Research Foundation Of State University Of New York | Stapled peptides and method of synthesis |
| WO2015114062A1 (en) * | 2014-01-29 | 2015-08-06 | Universite De Strasbourg | New target for diabetes treatment and prevention |
| EP3421485A1 (en) * | 2017-06-30 | 2019-01-02 | Université de Strasbourg | Peptides for treatment and prevention of hyperglycaemia |
| US11530241B2 (en) * | 2017-12-14 | 2022-12-20 | Universite De Strasbourg | Peptides for treatment and prevention of nonalcoholic fatty liver disease and fibrosis |
| EP3743092A4 (en) * | 2018-01-23 | 2021-10-20 | Gila Therapeutics, Inc. | PHARMACEUTICAL PEPTIDE-YY FORMULATIONS, COMPOSITIONS, AND PROCEDURES |
-
2019
- 2019-12-20 ES ES19835292T patent/ES2948264T3/es active Active
- 2019-12-20 CN CN202211595960.8A patent/CN116196399A/zh active Pending
- 2019-12-20 KR KR1020217022834A patent/KR102555817B1/ko active IP Right Grant
- 2019-12-20 KR KR1020237023537A patent/KR20230110659A/ko active Search and Examination
- 2019-12-20 US US17/415,796 patent/US20220133860A1/en active Pending
- 2019-12-20 PT PT198352924T patent/PT3897697T/pt unknown
- 2019-12-20 SI SI201930555T patent/SI3897697T1/sl unknown
- 2019-12-20 EP EP19835292.4A patent/EP3897697B1/en active Active
- 2019-12-20 SG SG11202107923WA patent/SG11202107923WA/en unknown
- 2019-12-20 CA CA3124260A patent/CA3124260C/en active Active
- 2019-12-20 HR HRP20230591TT patent/HRP20230591T1/hr unknown
- 2019-12-20 FI FIEP19835292.4T patent/FI3897697T3/fi active
- 2019-12-20 BR BR112021012134-0A patent/BR112021012134A2/pt unknown
- 2019-12-20 MX MX2021007460A patent/MX2021007460A/es unknown
- 2019-12-20 AU AU2019408382A patent/AU2019408382A1/en active Pending
- 2019-12-20 IL IL284029A patent/IL284029B2/en unknown
- 2019-12-20 EA EA202191758A patent/EA202191758A1/ru unknown
- 2019-12-20 EP EP23164245.5A patent/EP4233890A3/en active Pending
- 2019-12-20 DK DK19835292.4T patent/DK3897697T3/da active
- 2019-12-20 CN CN201980089191.4A patent/CN113301916B/zh active Active
- 2019-12-20 LT LTEPPCT/EP2019/086573T patent/LT3897697T/lt unknown
- 2019-12-20 HU HUE19835292A patent/HUE062537T2/hu unknown
- 2019-12-20 JP JP2021535845A patent/JP7335337B2/ja active Active
- 2019-12-20 PL PL19835292.4T patent/PL3897697T3/pl unknown
- 2019-12-20 RS RS20230465A patent/RS64265B1/sr unknown
- 2019-12-20 WO PCT/EP2019/086573 patent/WO2020127904A1/en active Application Filing
-
2021
- 2021-07-20 ZA ZA2021/05101A patent/ZA202105101B/en unknown
-
2023
- 2023-06-26 CY CY20231100298T patent/CY1126054T1/el unknown
- 2023-08-17 JP JP2023133077A patent/JP2023159268A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL275777A (en) | Improved peptide drugs for the treatment of NASH and other disorders | |
| ZA201908165B (en) | Compounds for the prevention and treatment of diseases and the use thereof | |
| ZA201905851B (en) | Peptides and methods for the treatment of diabetes | |
| IL270199A (en) | Peptides for the treatment of diabetes | |
| EP3694523A4 (en) | METHODS AND SUBSTANCES FOR PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISEASES | |
| IL284029A (en) | Peptides for the treatment and prevention of diabetes and related disorders | |
| IL272097A (en) | Compounds for the prevention and treatment of medical disorders and their uses | |
| ZA202000558B (en) | Prevention and/or treatment of neurodegenerative disease | |
| IL269400A (en) | Medicines and preparations for the treatment of eye disorders | |
| IL282519A (en) | Peptide fragments for the treatment of diabetes | |
| EP3713561A4 (en) | PHARMACEUTICAL COMBINATIONS AND METHODS OF TREATMENT FOR DIABETES AND RELATED DISEASES | |
| GB201704429D0 (en) | Calcitonin mimetics for treating diseases and disorders | |
| GB2603379B (en) | Avocatin B for the treatment of diseases and conditions | |
| EP3732204A4 (en) | ANTI-RENALASE ANTIBODIES TO TREAT AND PREVENT DISEASES AND DISORDERS | |
| GB201813677D0 (en) | Calcitonin mimetics for treating diseases and disorders | |
| GB201815000D0 (en) | Treatment of hypothroidism and related conditions | |
| SG11202007642RA (en) | Treatment of disorders with tasimelteon | |
| GB201812276D0 (en) | Treatment of cognitive disorders | |
| GB201809408D0 (en) | Treatment of Cognitive Disorders | |
| GB201711838D0 (en) | Calcitonin mimetics for treating diseases and disorders | |
| GB201805556D0 (en) | Treatment of ophthalmological conditions | |
| GB201719969D0 (en) | Prevention and/or treatment of neurodegenerative disease | |
| GB201704355D0 (en) | Calcitonin mimetics for treating diseases and disorders | |
| AU2017904032A0 (en) | Implants for the Treatment of Diseases and Disorders |